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MinireviewFinding the Intracellular
Signaling Pathways Affected
by Mood Disorder Treatments
and course, it is not surprising that bipolar disorder, like
other mood disorders, is considered to have heteroge-
neous etiologies. Nevertheless, twin, adoption, and fam-
ily studies indicate that bipolar disorder is highly herita-
ble and that first-degree relatives are also at increased
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risk for recurrent depression. Recent genome-wide2 Yale University School of Medicine
screens have uncovered several loci on the human ge-Connecticut Mental Health Center
nome significantly associated with the risk for bipolarNew Haven, Connecticut 06508
disorder, although no specific gene has yet to be identi-
fied (Sklar, 2002). Notably, some of these loci overlap
with loci associated with increased risk for schizophre-Postmortem and brain imaging studies have revealed
nia. While bipolar disorder has been associated withstructural changes and cell loss in cortico-limbic re-
creativity, in its severe forms, bipolar disorder can begions of the brain in bipolar disorder and major depres-
quite disabling and bears the lifetime risk for suicide ofsion. Consistent with these findings, mood stabilizers
15% when untreated.such as lithium ion and valproic acid, which are used
Postmortem and brain imaging studies have recentlyto treat bipolar disorder, as well as antidepressants
revealed a number of structural changes in the brain inand electroconvulsive therapy have recently been
bipolar disorder, demonstrating the presence of mor-shown to activate interconnected intracellular signal-
phological as well as neurochemical abnormalitiesing pathways that promote neurogenesis and synaptic
(Manji et al., 2001). Significant reductions in the volumesplasticity. These insights should assist in understand-
of prefrontal cortex and the hippocampus have beening the pathophysiology of severe mood disorders as
reported with structural magnetic resonance (MR) im-well as aid in the development of more effective treat-
aging. The latter is also observed in major depressivements.
disorder. Significant reductions in the number of glia
and size of neurons have been shown in prefrontal cor-For nearly 50 years, theories about the mechanisms of
tex, and reductions in presynaptic markers for GABAer-actions of drugs used to treat neuropsychiatric disor-
gic interneurons occur in subsectors of the hippocam-ders have focused primarily on their effects on synaptic
pus (Ongur et al., 1998). MR spectroscopy has alsoneurotransmission, such as inhibition of neurotrans-
shown reduced levels of N-acetylaspartate, a markermitter reuptake (serotonin-specific reuptake inhibitors
for neuronal functional integrity, in prefrontal cortex[SSRI]), blockade of neurotransmitter receptors (anti-
(Moore et al., 2000a). Together these findings supportpsychotics), or inhibition of neurotransmitter catabolism
the hypothesis that neuronal atrophy and cell loss con-(monoamine oxidase inhibitors [MAOI]). However, sev-
tribute to the pathophysiology of mood disorders.eral treatments for severe mood disorders, especially
Treatment of bipolar disorder involves two separatebipolar disorder, have no obvious effects on synaptic
but related considerations. First, the patient in an epi-neurotransmission. These include the monovalent cat-
sode of mania or depression should be restored to aion lithium (Li), the anticonvulsants valproic acid (VPA)
normal mood. Second, mood fluctuations must be atten-and carbamazepine, and electroconvulsive therapy
uated to prevent the recurrence of future episodes. ECT
(ECT). To understand the therapeutic action of these
is especially effective for restoring normal mood along
mood stabilizing drugs as well as antidepressants, in-
with other symptomatic treatments, such as antidepres-
vestigators have recently begun to examine their effects sants and antipsychotics, whereas Li and the anticon-
on intracellular signaling pathways that regulate gene vulsants VPA and carbamazepine have been shown to
expression and have identified common pathways that stabilize mood and to reduce significantly the recur-
promote neurotrophic effects (Duman et al., 2000; Manji rence of mania and/or depression. However, mood sta-
et al., 2001). This minireview will focus on signaling path- bilization does not extend to all anticonvulsants, as ga-
ways for both mood stabilizing and antidepressant med- bapentin, topiramate, and phenytoin have been shown
ications because common targets have been identified to be ineffective.
for both classes of drugs and because antidepressants In attempting to identify sites of therapeutic action of
are often prescribed in combination with Li and VPA. these agents in experimental models, several considera-
For a more detailed analysis of the neurobiology of mood tions must be kept in mind (Manji and Lenox, 1999).
disorders, see Nestler et al. (2002). First, the effects should occur at concentrations relevant
Bipolar disorder, also known as manic-depressive ill- to the therapeutic action of the drugs in patients and
ness (MDI), is characterized by recurrent fluctuations in not simply be the consequence of toxic levels of the
mood. There is a substantial range in its clinical manifes- drugs. Second, the effects should occur only after
tations, including regular episodes of depression and chronic exposure, which mirrors the delayed onset of
mania, recurrent depression with minimal mood eleva- therapeutic response in the clinical setting. Third, the
tion, and the more treatment resistant rapid cycling and intracellular pathways affected should involve neuronal
mixed mood states. Given the variation in symptoms systems that have relevance to mood regulation. Finally,
as genes of risk are identified, the affected pathway
might be linked to the function of specific genes.*Correspondence: joseph_coyle@hms.harvard.edu
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Figure 1. Schematic Representation of Intra-
cellular Pathways Affected by Mood Stabiliz-
ers and Antidepressants
Activation →; inhibition .
The first intracellular pathway implicated in the action ptotic effects of the ion (Klein and Melton, 1996). Further-
more, VPA and another anticonvulsant with moodof mood stabilizers was the phosphoinositol cycle (Fig-
ure 1). Fifteen years ago, Berridge and colleagues (1989) stabilizing effects, lamotrigine, also protect against apo-
ptosis due to GSK-3 inactivation and/or induction ofshowed that lithium is a noncompetitive inhibitor of ino-
sitol monophosphatase, which converts IP3 to myo-ino- -catenin (Phiel et al., 2001). VPA increases -catenin
gene expression by inhibition of histone deacetylase,sitol. Furthermore, VPA and lithium decrease the trans-
port of myo-inositol into the cell. These actions result which normally inactivates gene transcription by remov-
ing charged moieties on histones that expose DNA pro-in a depletion of IP3 and diacylglycerol (DAG), an activa-
tor of phosphokinase C (PKC). The concerted effects of moter elements (Phiel et al., 2001). Given these diverse
and multiple sites of action on processes regulatingchronic VPA or Li lead to a reduction in PKC activity,
particularly the PKC and PKC isoforms (Manji and embryogenesis and development, it is not surprising
that these mood stabilizers exert teratogenic effects inLenox, 1999). Recently, the mood stabilizer carbamaz-
epine has also been implicated in the phosphoinositol utero (Williams et al., 2002).
The mood stabilizers also influence signal transduc-cycle through the study of effects of mood stabilizers on
growth cone elaboration in cultured neurons (Williams et tion cascades that underlie the actions of neurotrophic
factors, including the phosphotidylinositol-3 kinase (PI-al., 2002). Li, VPA, and carbamazapine all increased the
spread of growth cones and inhibited their collapse, 3K)-Akt pathway and the ras-mitogen-activated protein
kinase (MAPK) cascade (Chuang et al., 2002). The PI-an effect that could be overcome by exogenous myo-
inositol. Furthermore, inhibitors of prolyl oligopeptidase, 3K-Akt pathway is best known for its ability to inhibit
programmed cell death by blocking proapoptotic fac-which elevate intracellular levels of IP3, reverse the ef-
fects of the mood stabilizers on growth cone expansion. tors. The MAPK cascade, which includes the extracellu-
lar signal regulated kinase (ERK), also supports cell sur-One of the substrates of PKC is myristoylated alanine-
rich C kinase substrate (MARCKS). MARCKS is also vival and promotes synaptic plasticity by regulating
several transcription factors, including the cyclic AMPimplicated in brain development, calcium/calmodulin
signaling, and membrane cytoskeletal restructuring. response element binding protein (CREB). Activation of
ERK stimulates ribosomal S6 kinase (RSK), which inBoth chronic Li and VPA decrease MARCKS expression
in the hippocampus and enhance neurite extension in turn activates CREB, but inhibits the proapoptotic factor
Bad. Chronic treatment with Li activates Akt, and VPAneuronal cultures (Manji and Lenox, 1999).
This theme of promoting neuronal plasticity by mood activates ERK and its downstream effectors RSK and
CREB (Yuan et al., 2001). Consistent with antiapoptoticstabilizers extends to the Wnt (wingless) signaling path-
way, which plays a prominent role in embryogenesis. effects in other signaling cascades affected by mood
stabilizers, inactivation of Bad and upregulation of Bcl-2,Wnt binds to a cell surface G protein-coupled receptor
that activates an intermediary kinase, “disheveled.” Ac- a target of CREB, were observed in the prefrontal cortex
(Chen et al., 1999). There are reciprocal relationshipstivated disheveled inhibits Glycogen Synthase Kinase-
3 (GSK-3), as does protein kinase A (Akt). GSK-3 between these pathways, as Akt activation inhibits GSK-
3 through serine (9) phosphorylation and overexpres-phosphorylates-catenin, thereby targeting it for degra-
dation. Thus, inhibition of GSK-3 promotes the accu- sion of GSK-3 prevents CREB phosphorylation in-
duced by brain-derived nerve growth factor (BDNF) (Maimulation of -catenin, which has antiapoptotic effects
and stimulates axonogenesis through activation of the et al., 2002).
The BDNF signaling cascade has been implicated inTcf/Lef-1 promoter. Li directly inhibits GSK-3 by com-
peting with Mg2, which may account for the antiapo- the mechanisms of action of ECT and antidepressants
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(Duman et al., 2000), and antidepressants are often co- more work is needed to substantiate these conclusions.
It is possible that alteration of these pathways in re-administered with mood stabilizers in patients in the
depressed phase of bipolar disorder. BDNF, a member sponse to drug treatment is an epiphenomenon, albeit
very interesting, that is unrelated to the therapeutic ac-of the nerve growth factor family, has been shown to
increase synaptic strength, survival, and growth of ma- tions of these agents. Further studies using mutant
mouse models and viral expression strategies areture neurons through activation of a transmembrane
receptor that contains intrinsic tyrosine kinase activity needed to demonstrate that alterations of these signal
transduction proteins are sufficient to produce cellular(TrkB). The abbreviation Trk comes from a troponin/
receptor kinase fusion protein first identified from a co- and behavioral effects observed with drug treatments
and, conversely, that blockade of these pathways canlon carcinoma. Chronic ECT or chemical antidepressant
treatment upregulates the expression of BDNF and TrkB inhibit the actions of drug treatments. In addition, im-
proved behavioral models are needed that have betterby increasing CREB and CRE-mediated gene expres-
sion (Chen et al., 2001b; Thome et al., 2000). ECT in- face validity for mood disorders or, more specifically,
for certain aspects of mood disorders. For example,creases neuronal sprouting in the rat hippocampus
through a process that is partially dependent on BDNF given the advances that have been made in understand-
ing the molecular and cellular mechanisms underlyingas shown by its reversal in BDNF null mutant mice.
Moreover, ECT and Li as well as other chemical antide- motivation and reward pathways in the brain, attention
has been given to testing the role of reward pathwayspressants increase new cell birth, or neurogenesis, in
adult brain (Malberg et al., 2000; Nestler et al., 2002). in anhedonia, one of the core symptoms of depression.
Finally, it will be important to test the role of these signalIncreased neurogenesis even occurs in the context of
elevated corticosterone, which causes hippocampal at- transduction pathways in different brain regions that
control different behaviors. For example, CREB in therophy (Czeh et al., 2001). Both elevated corticosterone
and hippocampal atrophy are often observed in severe nucleus accumbens is reported to influence drug reward
and could have different consequences than in the hip-depression (Manji et al., 2001).
In addition to increasing neurogenesis, ECT and pocampus (see Nestler et al., 2002).
The clinical relevance of these signaling pathways inchemical antidepressants have behavioral effects in ani-
mal models of depression. One of the most established the treatment of bipolar disorder and depression can
also be assessed by analysis of postmortem brains ofand well-characterized animal models for predicting an-
tidepressant effects is the learned helplessness para- affected individuals, linkage studies of the genes encod-
ing specific signaling molecules, as well as brain imagingdigm in which rats are subjected to repeated inescap-
able stress that results in failure to escape in subsequent studies. This is extremely difficult and slow work, and
although the findings are preliminary, they certainly aretesting. This “helplessness” response is reversed by
administration of antidepressants or ECT. Viral expres- supportive (Manji et al., 2001). For example, postmortem
studies demonstrate decreased levels of CREB and ERKsion of CREB in the dentate gyrus of the hippocampus
but not in the frontal cortex reversed the helplessness in depressed patients and increased levels of CREB and
BDNF in patients taking an antidepressant at the time(Chen et al., 2001a). That these effects are likely medi-
ated by BDNF/TrKB induction that occurs with chronic of death (D’Sa and Duman, 2002). In one study, a BDNF
allele (val66met) has been identified as a potential riskantidepressant treatment is supported by the demon-
stration that bilateral hippocampal infusion of BDNF is locus for bipolar disorder, although this effect has not
been replicated in different patient populations (Sklar,as effective as antidepressants in reversing the learned
helplessness behavioral response (Shirayama et al., 2002). The met allele results in abnormal intracellular
packaging of BDNF, and met allele carriers have poorer2002). In addition, infusions of inhibitors of TrkB or the
MAPK cascade block the effects of BDNF or chemical episodic memory and lower hippocampal NAA (Egan et
al., 2003). Further studies will be required to determineantidepressant treatment, further demonstrating a role
for the TrkB-MAPK cascade in the actions of antidepres- the specificity of altered BDNF expression and associa-
tion of BDNF alleles with mood disorders.sants (Shirayama et al., 2002; Saarelainen et al., 2003).
Thus, effective antidepressants, which increase the A structural MRI study has shown that the reduced
volume of gray matter in prefrontal cortex present insynaptic concentration of serotonin and/or norepineph-
rine, appear to activate the ERK/MAPK cascade by in- untreated bipolar disorder was not observed in bipolar
subjects receiving Li (Moore et al., 2000a). Furthermore,creased stimulation of upstream biogenic amine G pro-
tein-coupled receptors. These receptors can in turn Li treatment of bipolar disorder resulted in normalization
of cortical NAA levels (Moore et al., 2000b). In addition,activate the MAPK cascade via stimulation of second
messengers, such as cAMP, IP3, and Ca2, and their temporal lobe atrophy associated with major depression
appears to be reversed after effective antidepressantrespective protein kinases or via interactions with solu-
ble tyrosine kinases and other signaling pathways up- treatment. The delayed onset of the therapeutic effects
of several days to weeks after initiation of treatment isstream of MAPK. The activation of downstream tran-
scription factors such as CREB increases BDNF and consistent with the time course of the activation of these
neurotrophic signaling cascades.TrkB expression in limbic regions, resulting in neuronal
sprouting, increased neurogenesis, synaptic plasticity, Drugs used for the treatment of bipolar disorder and
depression have overlapping effects on certain signaland behavioral effects in models of depression.
Although these preclinical studies provide strong sup- transduction cascades, including the MAPK cascade,
but bipolar medications clearly have a different thera-port for the MAP kinase cascade as well as the cAMP-
CREB and GSK-3-catanein signaling pathways in the peutic profile than antidepressants. So what distin-
guishes these drugs and their therapeutic mechanisms?actions of mood stabilizers and antidepressants, much
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Moore, G., Bebchuk J.M., Wilds, I.B., Chen, G., Manji, H.K., andThis question also relates to one of the most difficult
Menji, H.K. (2000b). Lancet 356, 1241–1242.questions regarding the actions of mood stabilizing
Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J., anddrugs: how does treatment with one drug improve both
Monteggia, L.M. (2002). Neuron 34, 13–25.mania and depression, two opposites ends of the mood
Ongur, D., Drevets, W.C., and Price, J.L. (1998). Proc. Natl. Acad.spectrum. One hypothetical explanation may lie in un-
Sci. USA 95, 13290–13295.
derstanding how drugs interact with these extremes in
Phiel, C., Zhang, F., Huang, E.., Guenthe, M.G., Lazzar, M.A., andmood swings. Recurrent mood disorders as opposed
Klein, P.S. (2001). J. Bio. Chem. 276, 36734–36741.
to isolated episodes of depression may involve disrup-
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M.,
tions in circadian and/or ultradian rhythms, and mood MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et
stabilizers may normalize these rhythms in addition to al. (2003). Activation of the trkB neurotrophin receptor is induced
their effects on mood. In this regard, it is intriguing to by antidepressant drugs and is required for antidepressant-induced
behavioral effects. J. Neurosci. 23, 349–357.note that the Drosophila ortholog of GSK-3, shaggy,
Shirayama, Y., Chen, A.C.-H., Nakagawa, S., Russell, D., and Duman,phosphorylates TIMELESS, thereby regulating circadian
R.S. (2002). J. Neurosci. 22, 3251–3261.rhythms in the fruit fly (Martinek et al., 2001). If this
Sklar, P. (2002). Annu. Rev. Genomics Hum. Genet. 3, 371–413.mechanism extends to humans, it may be that the com-
Thome, J., Sakai, N., Shin, K.H., Steffen, C., Zhang, Y.-J., Impey, S.,bination of effects on mood as well as on circadian
Storm, D.R., and Duman, R.S. (2000). J. Neurosci. 20, 4030–4036.rhythms distinguish mood stabilizers from antidepres-
Williams, R., Cheng, L., Mudge, A.W., and Harwood, A.J. (2002).sants.
Nature 417, 292–295.Although remarkable progress has been made in our
Yuan, P., Juong, L.D., Jiang, Y.M., Gutkind, J.S., Manji, H.K., andunderstanding of the actions of mood stabilizing and
Chen, G. (2001). J. Biol. Chem. 276, 31674–31683.antidepressant medications on intracellular signaling
pathways, it is important to point out that this work
represents only the beginning. Further studies of these
intracellular cascades and interactions of these path-
ways with endocrine, metabolic, and environmental
forces will provide the framework for identifying the criti-
cal signaling pathways underlying treatment response
and, eventually, the etiology of mood disorders.
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